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PtdIns3P is recognized as an important player in the control of the
endocytotic pathway and in autophagy. Recent data also suggest
that PtdIns3P contributes to molecular mechanisms taking place
at the plasma membrane and at the midbody during cytokinesis.
This lipid is present in low amounts in mammalian cells and
remains difficult to quantify either by traditional techniques based
on radiolabelling followed by HPLC to separate the different
phosphatidylinositol monophosphates, or by high-sensitive liquid
chromatography coupled to MS, which is still under development.
In the present study, we describe a mass assay to quantify this lipid
from various biological samples using the recombinant PtdIns3P
5-kinase, PIKfyve. Using this assay, we show an increase in the
mass level of PtdIns3P in mouse and human platelets following
stimulation, loss of this lipid in Vps34-deficient yeasts and its
relative enrichment in early endosomes isolated from BHK cells.
Key words: class III phosphoinositide 3-kinase, mass assay,
PIKfyve, PtdIns3P.
INTRODUCTION
Phosphoinositides are considered as highly dynamic players in
the spatial and temporal organization of signalling networks
that regulate many important cellular processes, including
cytoskeleton organization, membrane trafficking or cell survival
and proliferation [1,2]. Among PtdInsPs (phosphatidylinositol
monophosphates), much attention has been paid to PtdIns3P
over the last few years. This lipid can be produced by the class
III and possibly by class II PI3Ks (phosphoinositide 3-kinases)
[3]. The mammalian class III PI3K, hVps34, was identified as
a homologue of Vps34, the only PI3K present in yeast [3–5],
which plays an important role in the regulation of the endocytic
pathway and in autophagy [5]. It has a lipid substrate specificity
restricted to PtdIns and is considered as the major producer of the
constitutive pool of PtdIns3P. It is still unclear whether class III
PI3K has a basal activity or if it is also regulated by extracellular
stimuli.
It is generally acknowledged that the amount of PtdIns3P does
not exceed 20–25% of the total PtdInsPs in mammalian cells,
whereas in yeast it represents nearly 50% of PtdInsPs. Using
biochemical approaches and fluorescence microscopy to localize
PtdIns3P with a specific probe [GFP (green fluorescent protein)–
2×FYVE], it has been demonstrated that this lipid is concentrated
in early endosomes [6]. PtdIns3P regulates membrane transport
and dynamics through the recruitment of proteins containing
FYVE or PX (Phox homology) domains [7]. For instance, EEA1
(early endosome antigen 1), a central regulator of endosome
fusion, is recruited to this compartment by Rab5-GTP and
PtdIns3P through interaction with its FYVE domain [8]. The
implication of PtdIns3P in the control of vesicular trafficking and
intracellular protein sorting has been well demonstrated in yeast
and in Caenorhabditis elegans, and accumulating data point to a
similar role in mammalian cells [4,6,9].
PtdIns3P and class III PI3K, in complex with beclin-1, have
also been shown to control the autophagic pathway [10,11].
In neutrophiles, they are important for the recruitment and the
assembly of proteins of the NADPH oxydase complex, including
p40phox, which binds PtdIns3P by its PX domain on phagosomes
[12,13].
However, the role of PtdIns3P is probably not confined to
endosomal/phagosomal structures. Evidence is accumulating that
this lipid can also act as a dynamic intracellular second messenger
[14,15]. Indeed, insulin stimulation induces the formation of a
pool of PtdIns3P at the plasma membrane, where it controls
the translocation of GLUT4 (glucose transporter 4) [15,16].
In contrast with PtdIns(3,4,5)P3 or PtdIns(3,4)P2, the global
level of PtdIns3P does not undergo rapid and dramatic increase
following mammalian cell stimulation. However, moderate and
transient changes have been reported in insulin-stimulated cells
[16] or in activated blood platelets [17], suggesting that besides
a pool of PtdIns3P that would act in the basal regulation of
trafficking, agonist-dependent pools of PtdIns3P can indeed be
generated. In this context, class II PI3Ks have been proposed to
be responsible for the synthesis of PtdIns3P upon cellular
stimulation by extracellular cues [18].
Finally, recent data suggest unexpected new functions for this
lipid in the control of cytokinesis [19] and the entry of pathogen
effectors into host cells [20]. Moreover, important changes in
the level of PtdIns3P have been reported in mammalian cells
infected by pathogens, such as Plasmodium falciparum and
Mycobacterium tuberculosis [21].
Abbreviations used: EEA1, early endosome antigen 1; GFP, green fluorescent protein; GST, glutathione transferase; MTM, myotubularin; MTMR, MTM-
related; PE, phosphatidylethanolamine; PI3K, phosphoinositide 3-kinase; PtdInsP, phosphatidylinositol monophosphate; PtdInsP2, phosphatidylinositol
diphosphate; PX, Phox homology; TRAP, thrombin-receptor-agonist peptide.
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© 2012 The Author(s)
The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.
18 G. Chicanne and others
Figure 1 Purification and substrate specificity of recombinant PIKfyve
(A) Recombinant PIKfyve was produced in SF9 insect cells, purified and analysed by Coomassie Blue (CB) staining or Western blotting (WB) using an anti-GST antibody. (B) The substrate
specificity of purified recombinant PIKfyve was evaluated using vesicles composed of three isomers of PtdInsP alone (i.e. C16:0/C16:0-PtdIns3P, natural PtdIns4P or C16:0/C16:0-PtdIns5P) or mixed
(Mix.) (10 % PtdIns3P, 80 % PtdIns4P and 10 % PtdIns5P, by weight). The products of the reactions were analysed by TLC (left-hand panel) and HPLC (right-hand panels). (C) Lipid vesicles
containing PE improved the substrate specificity of recombinant PIKfyve towards PtdIns3P. Vesicles composed of 99.25 % natural PE and 0.75 % of either C16:0/C16:0-PtdIns3P, natural PtdIns4P or
C16:0/C16:0-PtdIns5P were used as a substrate for purified recombinant PIKfyve. Lipid vesicles composed of a mixture (Mix.) of natural PE (99.25 %), C16:0/C16:0-PtdIns3P (0.075 %), natural PtdIns4P
(0.60 %) and C16:0/C16:0-PtdIns5P (0.075 %) (by weight) were also used as a substrate for recombinant PIKfyve. The products of the reactions were analysed as in (B). Results are representative of
three independent experiments. CTS, counts per second.
In addition to a tight control by class III, and probably
class II, PI3Ks, the amount of PtdIns3P is also regulated by
the PtdIns3P 5-kinase PIKfyve, PtdIns(3,4)P2 4-phosphatases
such as inositol polyphosphate 4-phosphatase type I and II,
and PtdIns3P 3-phosphatases of the MTM (myotubularin)
family [22,23]. Importantly, several MTM genes are mutated
in genetic diseases such as X-linked centronuclear myopathy
(for MTM1) and Charcot-Marie-Tooth 4B neuropathy [for
MTMR (MTM-related) 2 and MTMR13]. Mutations in the gene
encoding PIKfyve have been found in patients affected with
Franc¸ois-Neetens fleck corneal dystrophy [24,25] and knockout
experiments in mice have demonstrated that loss of PIKfyve leads
to early embryonic lethality [26]. Moreover, polyphosphate 4-
phosphatase type II is involved in cancer aggressiveness [27].
Although a clear implication of PtdIns3P modifications has not
been directly demonstrated in the aetiology of these pathologies,
an important role of this lipid in cell regulation is highly suspected.
Modifications of the level of PtdIns3P may act in concert
with scaffolding activities of the enzymes responsible for its
metabolism [22].
Quantifying the changes in PtdIns3P elicited by different
conditions is still challenging, and monitoring its amounts in
biopsies or isolated subcellular compartments remains difficult.
To separate and quantify the isomers of PtdInsP (PtdIns3P,
PtdIns4P and PtdIns5P), the classical method used requires
equilibrium [3H]inositol or [32P]Pi radiolabelling of cells, lipid
extraction and deacylation, followed by separation and analysis
by ion-exchange HPLC [28]. This method allows analysis of the
phosphoinositide content of cultured cell lines and of some
primary cells. However, it does not allow quantification
of biopsies of solid tissues and is relatively unsensitive
to minor phosphoinositides [particularly PtdIns5P, PtdIns3P
and PtdIns(3,5)P2]. Moreover, to discriminate between an
increase in mass or a change in the turn-over of
the phosphate on a phosphoinositide, it is essential to reach the
isotopic equilibrium, which is not always possible when primary
cells are used. To circumvent these drawbacks, a protocol
combining liquid chromatography and MS has been developed,
allowing analysis of phosphoinositides from lipid extracts of
biological samples [29]. This promising approach is still under
development and requires specific equipments and expertise to
enable routine profiling of phosphoinositides. It is still particularly
difficult to separate and quantify some of the isomers of
PtdInsP and PtdInsP2 (phosphatidylinositol diphosphate) by MS.
As an alternative, methods using protein domains selectively
recognizing a lipid in highly controlled conditions (recently
commercially available for different phosphoinositides) or a
kinase assay specifically phosphorylating a lipid (e.g. PtdIns5P
[30]) can be developed. In the present study, we propose a
convenient mass assay to accurately quantify PtdIns3P from
various biological samples, including yeast and mammalian cell
extracts by using recombinant PIKfyve.
MATERIALS AND METHODS
Materials
GMEM (Glasgow minimal essential medium) and FBS (fetal
bovine serum) were from Invitrogen. TRAP (thrombin-receptor-
agonist peptide)-7 was from Bachem. Silica gel G60 TLC
plates were from Merck. [32P]Pi and [γ -32P]ATP were from
PerkinElmer. Brain L-α-phosphatidylethanolamine and brain
L-α-PtdIns4P were from Avanti Polar Lipids. C16:0/C16:0-PtdIns3P
and C16:0/C16:0-PtdIns5P were from Echelon. The Saccharomyces
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Figure 2 Sensitivity and linearity of the PtdIns3P mass assay
(A) Vesicles composed of 20 nmol of natural PE and increasing amounts of pure C16:0/C16:0-PtdIns3P (from 0 to 100 pmol), as indicated, were submitted to the assay and the formed [32P]PtdIns(3,5)P2
was separated by TLC (upper panel) and quantified by HPLC (lower panel). (B) Increasing amounts of C16:0/C16:0-PtdIns3P (from 0 to 100 pmol) were added to 3×105 HeLa cell lysate. Lipids were
then extracted and PtdInsPs were TLC-purified and submitted to the PtdIns3P mass assay to check the sensitivity and linearity of the assay in a biological sample. [32P]PtdIns(3,5)P2 was quantified
in each sample by HPLC. The basal level of PtdIns3P detected in HeLa cells (10 pmoles/3×105 HeLa cells) was subtracted to each point of the curve. Results are the means +− S.D. from three
experiments. CTS, counts per second.
cerevisiae strains used in the present study were wild-type
(BY4741, MATa; his3Δ1; leu2Δ0; met15Δ0; ura3Δ0) and
vps34Δ (BY4741 vps34::KanMX4) and were purchased from
Euroscarf. All other reagents were purchased from Sigma–
Aldrich unless otherwise indicated.
Production of recombinant GST (glutathione transferase)–PIKfyve
The short form of murine PIKfyve was cloned and a plasmid
encoding the tagged enzyme at the N-terminus with GST was
generated. GST–PIKfyve protein was produced in SF9-infected
cells and purified (GTP-Technology). Briefly, after 36 h of
infection, SF9 cells were lysed by sonication in a buffer containing
10 mM NaPO4, pH7.4, 150 mM NaCl and a cocktail of inhibitors
composed of 4 mM Na3VO4, 5 μM iodoacetamide; 200 μM
TLCK (tosyl-lysylchloromethane), 2 μM benzamidine, 100 μM
AEBSF [4-(2-aminoethyl)benzenesulfonyl fluoride] and 1 mM
PMSF and centrifuged (20 min at 16000 g). The supernatant
fraction was incubated for 2 h with glutathione–agarose and
the GST–PIKfyve protein was eluted using an excess of
reduced glutathione and dialysed against 25 mM Hepes, pH 7.4,
containing 150 mM NaCl. Protein purification was assessed by
SDS/PAGE and Coomassie Blue staining as well as with Western
blotting with an anti-GST antibody. The purified enzyme was
aliquoted and kept at − 80 ◦C.
Cell preparation and lipid extraction
Yeast culture and lipid extraction were carried out as published
previously [31]. Whole blood was drawn from the inferior
vena cava of mice anaesthetized by intraperitoneal injection of
ketamine (100 mg/kg) and xylazine (10 mg/kg). Ethical approval
for animal experiments was received from the French Ministry
for Research in accordance with European Union guidelines.
Mouse platelets were isolated by successive centrifugations as
described previously [32]. Where indicated, platelets (5×108)
were pre-incubated at 37 ◦C with wortmannin (100 nM for
15 min). Platelets were then stimulated for 3 min with thrombin
(0.5 unit/ml) under aggregating conditions, and stimulation
was stopped by the addition of a mixture of CHCl3:CH3OH
(v/v). Lipids were immediately extracted by the acidic Bligh
and Dyer procedure [28,33]. For metabolic labelling, platelets
were incubated with 0.4 mCi/ml [32P]Pi, stimulated for 3 min
with thrombin (0.5 unit/ml) under aggregating conditions, and
their phosphoinositide content was analysed as described
previously [33]. Human platelets were isolated from blood
by successive centrifugation steps [33]. Peripheral blood was
collected from three healthy donors within the French National
Blood Establishment fulfilling the national principles of ethics and
the regulatory requirements. Research using human platelets was
carried out in accordance with the Declaration of Helsinki (2008)
of the World Medical Association. Before stimulation, platelets
(109) were preincubated at 37 ◦C for 10 min with fibrinogen
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Figure 3 Application of the PtdIns3P mass assay to yeast and mammalian cells
(A) The amount of PtdIns3P was quantified in wild-type (WT) or vps34-deleted S. cerevisae (Vps34) using the mass assay. The amount of PtdIns3P found is expressed as pmole/μmole of total
phospholipids (PL) determined by lipid phosphorus assay. Results are the means +− S.E.M. from three independent experiments. **P < 0.01 according to Student’s t test. (B) The amount of PtdIns3P
was quantified in resting mouse platelets and in platelets stimulated by 0.5 unit/ml thrombin and pre-incubated or not with wortmannin (100 nM for 15 min). Results are expressed as pmole of
PtdIns3P in 5×108 platelets and are the means +− S.E.M. from six independent experiments. (C) 32P-labelled mouse platelets were stimulated by 0.5 unit/ml thrombin for 3 min and the level
of [32P]PtdIns3P was quantified by HPLC. Results are expressed as the fold increase compared to the level measured in resting platelets, and are the means +− S.E.M. of two independent experiments.
(D) The amount of PtdIns3P was quantified from human platelets stimulated by 50 μM TRAP for the indicated times (4 or 8 min) in the presence of fibrinogen, with or without wortmannin pretreatment
(100 nM for 15 min). Results are expressed as fold increase and are means +− S.E.M. of three independent experiments (three different donors). (E) PtdIns3P was quantified in the post-nuclear
fraction (PNS) of BHK cells and in isolated early (EE) and late endosomal (LE) fractions. Results are expressed as fold increase and are the means +− S.E.M. from three independent experiments. As
a control of fractionation, a representative Western blot shows the localization of the early endosome protein EEA1. **P < 0.01 and ***P < 0.001 determined by one-way ANOVA test.
(250 μg/ml) and, when indicated, with wortmannin (100 nM for
15 min) before the addition of fibrinogen. Platelets were then
stimulated for the indicated times with TRAP (50 μM). The lipid
extraction was performed following the same procedure as for
mouse platelets.
Endosomal fractions were isolated from BHK cells as described
previously [34].
Lipid phosphorylation and analyses
Lipids extracted from the different cells or subcellular fractions
were resolved by TLC using a solvent of CHCl3:CH3OH:4.3 M
NH4OH (90/70/20, by vol.) on silica-coated glass plates pre-
activated for 30 min at 70 ◦C after migration in a solution of
50% (v/v) CH3OH, 1% potassium oxalate and 2 mM EDTA.
The migration of authentic standards visualized by iodine vapours
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Figure 4 Schematic representation of the major steps of the mass assay
(A) The different steps of the mass assay are summarized. (B) Schematic representation of the PtdInsPs isolation procedure.
allowed the localization of PtdInsPs in the different samples,
which were protected from the iodine vapors by a glass plate.
PtdInsPs were then scraped off and extracted by the acidic Bligh
and Dyer procedure [28,33].
For vesicle formation, PE (phosphatidylethanolamine; 20
nmoles) was added to TLC-purified PtdInsPs or commercial
PtdInsPs when indicated and dried under nitrogen. Dried lipids
were then resuspended in 30 μl of lipid kinase buffer (25 mM
Hepes, 150 mM NaCl, 1.7 mM EDTA, 1.7 mM dithiothreitol and
8 mM 2-glycerophosphate) and sonicated twice for 30 s in a
bath sonicator (45 kHz). After the addition of MgCl2 (2.5 mM),
ATP (50 μM, final concentration) and 0.2 μg of recombinant
GST–PIKfyve, phosphorylation reactions were initiated by
the addition of 20 μCi of [γ -32P]ATP. After incubation at
37 ◦C for 15 min, phosphorylated lipids were extracted and
analysed by TLC using a solvent of CHCl3:CH3OH:4.3 M
NH4OH (90/70/20, by vol.) as described above. The radioactive
PtdInsP2 products formed were scraped off, deacylated and
futher analysed by HPLC [28,33]. A standard curve with known
concentrations of C16:0/C16:0-PtdIns3P was processed under the
same conditions.
The amount of phospholipids in yeast was quantified by
phosphorus measurement by the Fiske and SubbaRow [35]
method.
RESULTS AND DISCUSSION
To develop a PtdIns3P mass assay capable of determining
accurately the amount of this lipid in cell extracts, we used
recombinant PIKfyve and [γ -32P]ATP to produce and quantify
radiolabelled PtdIns(3,5)P2 formed from PtdIns3P. Recombinant
GST–PIKfyve protein was produced in the baculovirus-SF9
insect cell system and the purified enzyme (Figure 1A) was
stable for months at − 80 ◦C. Its substrate specificity was first
evaluated using pure C16:0/C16:0-PtdIns3P, PtdIns4P purified from
brain extracts and C16:0/C16:0-PtdIns5P. PtdIns3P was efficiently
phosphorylated into PtdIns(3,5)P2 by recombinant PIKfyve as
demonstrated by the HPLC analysis (Figure 1B, panel 1).
As expected, PtdIns5P was not phosphorylated by PIKfyve.
However, when PtdIns4P purified from brain extract was used
as a substrate, we observed the production of radiolabelled
PtdIns(3,5)P2 (Figure 1B, panel 2), suggesting that some PtdIns3P
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was present in the samples, since the procedure used to purify
PtdIns4P from the brain does not preclude contamination with
other PtdInsPs. Recombinant PIKfyve also phosphorylated small
amounts of PtdIns4P into PtdIns(4,5)P2, as shown by the HPLC
analysis (Figure 1B, panel 2). When a mixture of PtdInsPs
containing 80% PtdIns4P, 10% PtdIns3P and 10% PtdIns5P
was used to reproduce the ratio classically found in resting
mammalian cells, PtdIns3P appeared as the preferred substrate
of recombinant PIKfyve (Figure 1B, panel 4). However, to
further decrease the residual phosphorylation of PtdIns4P, which
could cause a bias of quantification since it is much more
abundant in mammalian cells than PtdIns3P, we optimized the
assay by testing different conditions, especially variation of ions
concentrations and lipid vesicle composition. Interestingly, in the
presence of 0.4 μM PE and 2.5 mM MgCl2, recombinant PIKfyve
selectively phosphorylated PtdIns3P (Figure 1C). Under these
conditions, even with a large excess of PtdIns4P (80% PtdIns4P,
10% PtdIns3P and 10% PtdIns5P), PIKfyve produced 50-fold
more PtdIns(3,5)P2 than PtdIns(4,5)P2 (Figure 1C, panel 4).
The assay was found to be linear with pure PtdIns3P quantities
varying from a few pmol up to 100 pmol (Figure 2A). To
assay the linearity in the context of a cellular extract, increasing
amounts of pure PtdIns3P were then mixed with HeLa cell lysates
(Figure 2B). Again, the assay was linear over a relatively large
range of concentrations, indicating that the method displayed
good sensitivity. However, it is noteworthy that the yield of lipid
extraction is different from one biological sample to another (i.e.
cultured cells, yeasts or biopsies such as muscle extracts), mostly
because of the difference in mechanical resistance of tissues
compared with cultured cells, and must therefore be optimized
to accurately quantify PtdIns3P.
As a proof of principle, we tested our assay by measuring
the amount of PtdIns3P in yeast, where the only PI3K present
is encoded by the vps34 gene. In this model, a previous
study demonstrated that PtdIns3P could hardly be detected by
[3H]inositol labelling and HPLC analysis in the vps34-deleted
strain [4]. Accordingly, lipid extraction and mass assay showed
a dramatic decrease of PtdIns3P in the vps34-deleted strain
(Figure 3A), demonstrating that the mass assay is accurate in
quantifying PtdIns3P in yeasts. To further validate the assay,
we used mouse platelets stimulated by thrombin. As shown
in Figure 3(B), the mass of PtdIns3P increased following
stimulation, whereas inhibition of PI3Ks by wortmannin impaired
this elevation. Importantly, the increase in PtdIns3P measured
by the mass assay correlated with the increase in 32P-PtdIns3P
detected by HPLC after metabolic labelling in a parallel
experiment (Figure 3C). We also observed an increase in the
mass of PtdIns3P in human platelets stimulated through
the thrombin receptor PAR1 (protease-activated receptor 1)
with the agonist peptide (TRAP) in the presence of fibrinogen
to fully engage the integrin GpIIbIIIa (Figure 3D). Again,
preincubation of platelets with the PI3K inhibitor wortmannin
abolished the PtdIns3P production measured after 8 min of TRAP
stimulation (Figure 3D). These results are consistent with a
previous report showing an increase in 32P-labelled PtdIns3P upon
stimulation under similar conditions using HPLC analysis, after
metabolic labelling of human platelets [17]. Thus, in this case, the
incorporation of the radiolabel did reflect an increase in the mass
of this lipid. The role of PtdIns3P in stimulated platelets is still
unknown and the development of mouse models with deficiencies
in enzymes involved in its metabolism might bring new light on
the functions of this lipid in the near future.
To test whether our assay would be efficient to quantify
PtdIns3P in isolated subcellular compartments, we then separated
early and late endosomal fractions from BHK cells following
a well-established procedure [34]. We observed an enrichment
of the relative amount of PtdIns3P in early endosomes (10-
fold increase compared with the post-nuclear fraction) and to a
lesser extent in the late endosomal fraction when compared with
post-nuclear fractions (6-fold increase) (Figure 3E). Subcellular
fractionation can induce artifactual changes in lipid levels
due to potential transfer of material or to modification of
their metabolism during the isolation procedure. However, the
results of our mass assay are consistent with the imaging
data showing that the GFP–2×FYVE probe used in living
cells to visualize PtdIns3P pools preferentially decorates early
endosomes [6].
Overall, these results validate the application and the sensitivity
of the mass assay we developed in various biological samples (i.e.
yeast, primary human cells and isolated subcellular fractions).
This assay is relatively simple (Figure 4), robust and should be
useful to quantify PtdIns3P in various tissues from mice deficient
for PtdIns3P-metabolizing enzymes (i.e. Vps34, PIKfyve, MTMs,
inositol polyphosphate 4-phosphatase type I and II) or models
exhibiting knockin forms of these enzymes that are under
development. Accordingly, we already validated this assay by
measuring the amount of PtdIns3P in muscle samples from
mice deficient for myotubularin 1 and infected with wild-type or
inactive MTM1-expressing adeno-associated virus (L. Amoasii,
K. Hnia, G. Chicanne, A. Brech, B. S. Cowling, M. Mueller,
Y. Scwab, P. Koebel, A. Ferry, B. Payrastre and J. Laporte,
unpublished work).
In conclusion, we propose a new sensitive mass assay for
PtdIns3P quantification in various samples with significant
advantages compared with the method requiring radiolabelling
of cultured cells followed by HPLC analysis.
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